

Can't find Mestinon? Learn about alternatives to Pyridostigmine for myasthenia gravis and POTS, including Neostigmine, Azathioprine, and more.
If you rely on Mestinon (Pyridostigmine Bromide) to manage myasthenia gravis, POTS, or another condition, running out isn't just inconvenient — it can be dangerous. Muscle weakness can worsen quickly, and for some patients, going without medication means struggling to swallow, breathe, or get through the day.
With ongoing supply issues affecting Mestinon — especially the extended-release formulation — many patients are asking: What are my alternatives?
In this post, we'll cover what Mestinon does, how it works, and the real alternative medications your doctor might consider if you can't fill your prescription.
Mestinon is the brand name for Pyridostigmine Bromide, a cholinesterase inhibitor. It works by blocking an enzyme called acetylcholinesterase, which normally breaks down acetylcholine — a chemical messenger your nerves use to tell your muscles to contract.
By slowing the breakdown of acetylcholine, Mestinon allows more of it to build up at the neuromuscular junction. This means your nerve signals get through more effectively, which improves muscle strength and function.
Mestinon is FDA-approved for myasthenia gravis and is also widely used off-label for POTS, orthostatic hypotension, and Long COVID-related fatigue. For a deeper look at the drug, see our guide on what Mestinon is and how to take it.
Important: Never stop taking Mestinon or switch medications without talking to your doctor first. The alternatives below require a prescription and medical supervision.
Neostigmine is the closest alternative to Mestinon. Like Pyridostigmine, it's a reversible cholinesterase inhibitor that works by the same mechanism — blocking the breakdown of acetylcholine at the neuromuscular junction.
Key differences from Mestinon:
Neostigmine is a reasonable substitute if Mestinon is unavailable, but the dosing schedule and side effect profile are different, so your doctor will need to adjust your regimen carefully.
Ambenonium is another cholinesterase inhibitor that has been used for myasthenia gravis. It has a longer duration of action than both Pyridostigmine and Neostigmine, which means fewer doses per day.
However, Ambenonium has significant limitations:
Your doctor may consider it in specific situations, but availability is a practical barrier.
Azathioprine takes a completely different approach. Instead of boosting acetylcholine at the neuromuscular junction, it's an immunosuppressant that targets the underlying autoimmune process in myasthenia gravis.
Key points about Azathioprine:
Azathioprine isn't a direct substitute for Mestinon's immediate symptom relief, but it may be part of a broader treatment strategy that reduces your dependence on cholinesterase inhibitors.
Mycophenolate is another immunosuppressant used off-label for myasthenia gravis. Like Azathioprine, it targets the autoimmune component of the disease rather than providing immediate symptom relief.
Before looking at entirely different medications, consider whether a formulation switch might solve your problem:
Losing access to Mestinon is stressful, especially when you depend on it daily. The most important step is to talk to your doctor before making any changes. They can help you find the best alternative based on your specific condition, other medications, and medical history.
In the meantime, use Medfinder to search for Mestinon availability near you — you might find it at a pharmacy you haven't tried yet. And for tips on reducing cost, check out our guide on how to save money on Mestinon.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.